

ASX Code: GSS

20 April 2018

European approval expands product suite

- **CE-IVD registration has been confirmed for Genetic Signatures' EasyScreen™ ESBL & CPO ('antibiotic resistance') Detection Kit**
- **EasyScreen™ ESBL & CPO Detection Kit adds to the expanding list of products approved for sale in Europe (which includes the Enteric range)**
- **Registration process was accelerated by Genetic Signatures to meet market demand**
- **Commercial release is expected to improve diagnostic times, fast-tracking treatment and thereby saving lives**
- **Domestic approval for the EasyScreen™ ESBL & CPO Detection Kit is expected in the coming quarter**

Genetic Signatures Limited (ASX: GSS, "**Genetic Signatures**" or the "**Company**") is pleased to announce it has received CE-IVD registration for the sale of its Extended Spectrum Beta-Lactamase and Carbapenemase Producing Organisms ("**ESBL & CPO**") Detection Kit in Europe. The kit detects hospital 'superbugs' or 'antibiotic resistant' pathogens which are a significant global concern in healthcare settings as standard treatments may be rendered ineffective.

The EasyScreen™ ESBL & CPO Kit allows for rapid detection in less than 3 hours with minimal hands-on time for laboratory technicians. The Detection Kit has been designed to provide rapid and accurate detection of 16 Beta-lactam and Carbapenem resistant pathogen targets.

Genetic Signatures can now sell its EasyScreen™ ESBL & CPO Detection Kit across Europe through a hybrid of direct and distributor-led sales. Recruitment is currently underway to build GSS's direct sales team in Europe.

The CE-IVD registration follows successful clinical validation results and a clear market need for the EasyScreen™ ESBL & CPO Detection Kit.

Genetic Signatures CEO, Dr. John Melki commented:

"We are very excited to receive a major international approval for our EasyScreen™ technology. This registration follows significant work from the Genetic Signatures team and ultimately reflects the significant potential of our 3base™ technology to make a real difference in pathogen detection and treatment processes.

ESBL & CPO is now our second approved product group for sale in Europe, which will further increase the relevance of our product suite and sales potential with European customers. We are excited for our European sales team to present to new and existing customers with our expanded product suite."

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Chief Executive Officer
john@geneticsignatures.com
T: +61 (0)2 9870 7580

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**[™]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures' proprietary MDx **3base**[™] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.